In re Lamictal Direct Purchaser Antitrust Litig., No. 12-00995 (D.N.J.)
In re Lamictal Direct Purchaser Antitrust Litig., No. 12-00995 (D.N.J.)
In the Lamictal case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of SmithKline Beacham’s Lamictal, prescription drugs used to treat epilepsy, bipolar disorder and other medical conditions. The class also includes di
In the Lamictal case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of SmithKline Beacham’s Lamictal, prescription drugs used to treat epilepsy, bipolar disorder and other medical conditions. The class also includes direct purchasers of generic versions of Lamictal from Teva, SmithKline’s co-defendant and alleged co-conspirator. The complaint alleges that SmithKline entered a reverse payment patent settlement with Teva to delay launching its first filed generic to compete with SmithKline’s $2 billion a year Lamictal Tablets. Such an agreement violates §§ 1 and 2 of the Sherman Act.
